Cizzle Biotechnology has started the commercial rollout of its CIZ1B lung cancer blood test in the United States, moving the technology from laboratory validation into clinical availability.
The test is being introduced through Cizzle Bio, the company’s North American licensing partner, and will initially be available to licensed healthcare providers in the Dallas-Fort Worth and San Antonio areas of Texas.
This is the first commercial launch of the CIZ1B test in the US and marks a clear change in Cizzle Biotechnology’s development profile. The company is now beginning the process of building clinical use, establishing demand and supporting a wider commercial network.
Cizzle Bio holds exclusive rights to commercialise the test in the United States, Canada and the Caribbean. The Texas launch provides a controlled starting point in a large healthcare market, allowing the partners to assess how the test is used by physicians before expanding into additional regions.
The test has completed laboratory validation at OmniHealth Diagnostics, a Dallas-based laboratory operating under Clinical Laboratory Improvement Amendments certification. OmniHealth will process blood samples and issue results, providing the laboratory infrastructure required for the first stage of commercial delivery.
CIZ1B is designed to detect a protein variant associated with early-stage lung cancer from a standard blood sample. It is intended to support existing diagnostic methods rather than replace them. The test may be used alongside low-dose computed tomography scans and other clinical assessments, particularly where a patient has a suspicious scan result or requires further risk evaluation.
Cizzle Biotechnology Holdings plc (LON:CIZ) is a pioneering cancer diagnostics company, originally a spin-out from the University of York, and now listed on the London Stock Exchange.
